Format

Send to

Choose Destination
Anticancer Res. 2015 Nov;35(11):6147-52.

Long-term Follow-up After Interstitial Laser Thermotherapy of Breast Cancer.

Author information

1
Department of Surgery, Lund University and Lund University Hospital, Lund, Sweden kristinh@landspitali.is.
2
Department of Surgery, Lund University and Lund University Hospital, Lund, Sweden.
3
Department of Pathology, Lund University and Lund University Hospital, Lund, Sweden.

Abstract

AIM:

To review the effect of immunological changes induced by interstitial laser thermotherapy (ILT) on long-term outcome of patients with breast cancer.

PATIENTS AND METHODS:

Twenty-four patients with invasive breast cancer were treated with ILT followed by standard surgical excision. Immunohistological reactions on immunocompetent cells were performed on specimens obtained before and after ILT. Follow-up time was 116 (range=91-136) months.

RESULTS:

Significant prognostic factors were histologically-positive axillary lymph nodes and Ki67 positivity. ILT increased cytotoxic T (CD8(+)) lymphocytes within the tumor and mature dendritic cells (CD83(+)) and reduced the number of T-regulatory cells (Treg) CD25(+)/Forkhead box p3(+) (FOXP3(+)) lymphocytes in regional lymph nodes. These changes did not correlate with prognosis. The number of CD8(+) cells within the tumor, both before and after treatment, was significantly higher in patients with recurrence than in those without recurrence (p<0.01 and p<0.05, respectively). Patients with recurrent disease had a lower number of CD57(+) cells in tumor-free lymph nodes than did patients without recurrence (p<0.05).

CONCLUSION:

ILT did not have any long-term adverse effects. The clinical impact of the supposedly favourable immune changes after ILT should be examined in a larger patient population.

KEYWORDS:

Breast cancer; laser thermotherapy; minimally invasive treatment; therapy; thermal treatment; tumor immunology

PMID:
26504041
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center